Published :
Tables : 60
Figures : 49
Category : Healthcare
No. of Pages : 220
Report Code : HC-U3322
Neuroendocrine Carcinoma Treatment Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027. Neuroendocrine tumor is a malignant and a rare disorder that covers over one percent of all the malignant disorders. Neuroendocrine carcinoma develops in different organs like intestines, kidneys, lungs, GI tract and brain. This cancer type occurs in the neuroendocrine system of humans and produces hormones that are like neuroendocrine cells. As per the America Society of Clinical Oncology, over 11,000 people in the United States are diagnosed with neuroendocrine carcinoma every year. Furthermore, as pe the U.S Surveillance Epidemiology and End Results Register, the prevalence of gastrointestinal neuroendocrine carcinoma has risen by over 300% as compared to 1981, thus offering an opportunity for neuroendocrine carcinoma treatment market growth. Additionally, growing investments in research and development for creating next-gen sequencing tools that are cost-effective and are used for developing advanced cancer therapies. With an increase in the number of clinical trials, this market is anticipated to witness substantial growth over the next few years. There are various treatment alternatives available for the neuroendocrine carcinoma like radiation therapy, chemotherapy and surgery. 5-Fluorouracil and Streptozocin are some of the drugs that are used for treating this cancer. Many key players are constantly making efforts in developing targeted therapies, thereby propelling the proliferation of the market. Targeted drugs like Sunitinib and Everolimus are used for the treatment of this cancer. Such a variety of drug alternatives for treatment shall bolster the proliferation of the market. Market Segmentation: By Site • Lung • Gastrointestinal • Pancreas • Brain • Others By Diagnostic Tools • Biopsy • Imaging • Serology • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into site, diagnostic tools and region. The site segment is fragmented into lung, gastrointestinal, pancreas, brain and others. The gastrointestinal segment accounted for the largest neuroendocrine carcinoma treatment market share and this can be attributed to unhealthy dietary choices leading to GI tract issues. Radiofrequency ablation is the only alternative for pancreatic neuroendocrine carcinoma tumor, and this shall bolster the augmentation of the market. On the other hand, disadvantages like tumor spread, bleeding and pancreatic fistula are predicted to restrain the market growth. The diagnostic tools segment is diversified into biopsy, imaging, serology and others. The serology segment is further divided into blood test, molecular tests, urine test and others. The imaging segment is categorised into X-ray, PET scan, CT scan and others. The increased acceptance of novel diagnostic imaging methods that are capable of detecting minute and clinically insignificant tumors shall contribute in the growth of the market. Regional Analysis: The North America region is expected to dominate the market, and this can be credited to the rising prevalence of NETs in the United States which has increased the investments by key market players in developing advanced cancer therapies. As per the National Health Service, 2015, over 7,900 people are identified with carcinoid tumor in the United Kingdom each year and this shall rise during the forecasted timeframe, making Europe the second highest growing markets. Competitive Landscape: Some of the major market players are Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Pharmaceuticals Inc., Chiasma Inc., Aegis Therapeutics, Ispen, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics, Pfizer, Jubilant Life Sciences Ltd.(Jubilant DraxImage), AbbVie Inc., Delcath Systems Inc., Exelixis, Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global neuroendocrine carcinoma treatment market by site, by diagnostic tools and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Neuroendocrine tumor is a malignant and a rare disorder that covers over one percent of all the malignant disorders. Neuroendocrine carcinoma develops in different organs like intestines, kidneys, lungs, GI tract and brain. This cancer type occurs in the neuroendocrine system of humans and produces hormones that are like neuroendocrine cells. As per the America Society of Clinical Oncology, over 11,000 people in the United States are diagnosed with neuroendocrine carcinoma every year. Furthermore, as pe the U.S Surveillance Epidemiology and End Results Register, the prevalence of gastrointestinal neuroendocrine carcinoma has risen by over 300% as compared to 1981, thus offering an opportunity for neuroendocrine carcinoma treatment market growth. Additionally, growing investments in research and development for creating next-gen sequencing tools that are cost-effective and are used for developing advanced cancer therapies. With an increase in the number of clinical trials, this market is anticipated to witness substantial growth over the next few years. There are various treatment alternatives available for the neuroendocrine carcinoma like radiation therapy, chemotherapy and surgery. 5-Fluorouracil and Streptozocin are some of the drugs that are used for treating this cancer. Many key players are constantly making efforts in developing targeted therapies, thereby propelling the proliferation of the market. Targeted drugs like Sunitinib and Everolimus are used for the treatment of this cancer. Such a variety of drug alternatives for treatment shall bolster the proliferation of the market.
Market Segmentation:
By Site • Lung • Gastrointestinal • Pancreas • Brain • Others By Diagnostic Tools • Biopsy • Imaging • Serology • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into site, diagnostic tools and region. The site segment is fragmented into lung, gastrointestinal, pancreas, brain and others. The gastrointestinal segment accounted for the largest neuroendocrine carcinoma treatment market share and this can be attributed to unhealthy dietary choices leading to GI tract issues. Radiofrequency ablation is the only alternative for pancreatic neuroendocrine carcinoma tumor, and this shall bolster the augmentation of the market. On the other hand, disadvantages like tumor spread, bleeding and pancreatic fistula are predicted to restrain the market growth. The diagnostic tools segment is diversified into biopsy, imaging, serology and others. The serology segment is further divided into blood test, molecular tests, urine test and others. The imaging segment is categorised into X-ray, PET scan, CT scan and others. The increased acceptance of novel diagnostic imaging methods that are capable of detecting minute and clinically insignificant tumors shall contribute in the growth of the market.
Regional Analysis:
The North America region is expected to dominate the market, and this can be credited to the rising prevalence of NETs in the United States which has increased the investments by key market players in developing advanced cancer therapies. As per the National Health Service, 2015, over 7,900 people are identified with carcinoid tumor in the United Kingdom each year and this shall rise during the forecasted timeframe, making Europe the second highest growing markets.
Competitive Landscape:
Some of the major market players are Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Pharmaceuticals Inc., Chiasma Inc., Aegis Therapeutics, Ispen, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics, Pfizer, Jubilant Life Sciences Ltd.(Jubilant DraxImage), AbbVie Inc., Delcath Systems Inc., Exelixis, Inc.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global neuroendocrine carcinoma treatment market by site, by diagnostic tools and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Neuroendocrine Carcinoma Treatment Market, By Site Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Lung 7.2 Gastrointestinal 7.3 Pancreas 7.4 Brain 7.5 Others 8. Neuroendocrine Carcinoma Treatment Market, By Diagnostic Tools Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Biopsy 8.2 Imaging 8.2.1 X-Ray 8.2.2 PET Scan 8.2.3 CT Scan 8.2.4 Others 8.3 Serology 8.3.1 Blood Tests 8.3.2 Molecular Tests 8.3.3 Urine Tests 8.3.4 Others 8.4 Others 9. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 9.2.1. U.S. 9.2.2. Canada 9.2.3. Mexico 9.2.4 Rest of North America 9.3 Market Size (USD Mn) Forecast for North America 2020-2027 10. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 10.3.1. Brazil 10.3.2. Uruguay 10.3.3 Argentina 10.3.4. Rest of Latin America 10.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 11. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5 Switzerland 11.2.6. Spain 11.2.7. Russia 11.2.8. Poland 11.2.9. Rest of Western Europe 11.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 12. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1 Introduction 12.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 12.2.1 Japan 12.2.2 China 12.2.3 Singapore 12.2.4 Korea 12.2.5 India 12.2.6 Australia and New Zealand 12.2.7 ASEAN 12.2.8 Rest of Asia Pacific 12.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 UAE 13.2.2 South Africa 13.2.3 Egypt 13.2.4 Saudi Arabia 13.2.5 Rest of MEA 13.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 14.1 Novartis AG 14.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2 Amgen Inc. 14.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3 Boehringer Ingelheim GmbH 14.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4 Dauntless Pharmaceuticals 14.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Hutchison MediPharma Limited 14.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 AVEO Pharmaceuticals Inc. 14.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7 Chiasma Inc. 14.7.1. Company Overview (HQ, Business Segments, Employee Strength) 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8 Aegis Therapeutics 14.8.1. Company Overview (HQ, Business Segments, Employee Strength) 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9 Ispen 14.9.1. Company Overview (HQ, Business Segments, Employee Strength) 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10 Progenics Pharmaceuticals Inc. 14.10.1. Company Overview (HQ, Business Segments, Employee Strength) 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15 Impact of COVID-19 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. Competitive Intelligence and Competitive Matrix 16.1 Competitive Intelligence 16.2 Competitive Matrix 17. Major Deals and Strategic Alliances Analysis 17.1 Joint ventures 17.2 Mergers and acquisitions 17.3 Licensing and partnerships 17.4 Technology Collaborations 17.5 Strategic Divestments 17.6 Market Entry Strategies 18. Relevant Case Studies and Latest News Updates 19. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics